<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03524118</url>
  </required_header>
  <id_info>
    <org_study_id>1654-002</org_study_id>
    <secondary_id>MK-1654-002</secondary_id>
    <secondary_id>2017-005062-21</secondary_id>
    <nct_id>NCT03524118</nct_id>
  </id_info>
  <brief_title>Safety, Tolerability, and Pharmacokinetics of MK-1654 in Infants (MK-1654-002)</brief_title>
  <official_title>A Double-blind, Randomized, Placebo-controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MK-1654 in Pre-Term and Full-Term Infants</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and&#xD;
      incidence of anti-drug antibodies (ADAs) of single ascending doses of MK-1654 in healthy&#xD;
      pre-term (born at 29 to 35 weeks gestational age) and full-term (born at &gt;35 weeks&#xD;
      gestational age) infants. Participants will be randomized into 1 of 4 dose escalation panels&#xD;
      (Panels A to D); an additional panel (Panel E) of full-term infants will receive the same&#xD;
      dose as Panel D. Key safety and tolerability variables will be reviewed after each dose panel&#xD;
      prior to administering the next-highest dose.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Participants in Dose Panels A, B, C, D1, and E1 will be followed for up to 365 days. After&#xD;
      protocol Amendment 4 (AM4), participants in Dose Panels D2 and E2 will be followed for up to&#xD;
      545 days.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">September 20, 2018</start_date>
  <completion_date type="Anticipated">September 13, 2022</completion_date>
  <primary_completion_date type="Anticipated">September 13, 2022</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>Single ascending dose</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of participants experiencing a solicited injection site adverse event (AE)</measure>
    <time_frame>Up to Day 5</time_frame>
    <description>An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Solicited injection site AEs will be monitored from Day 1 to Day 5.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of participants experiencing a solicited systemic AE</measure>
    <time_frame>Up to Day 5</time_frame>
    <description>An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Solicited systemic AEs will be monitored from Day 1 to Day 5.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of participants experiencing a serious AE (SAE)</measure>
    <time_frame>Up to 545 days</time_frame>
    <description>An SAE is any untoward medical occurrence that, at any dose, results in death; is life-threatening; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent or significant injury/incapacity; is a congenital anomaly/birth defect; or is an other important medical event.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area under the serum-concentration time curve from zero to infinity (AUC0-∞)</measure>
    <time_frame>At designated time points (up to 1 year post-dose)</time_frame>
    <description>AUC0-∞ is a measure of the extrapolated mean concentration in serum from dosing to infinity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum serum concentration (Cmax) of MK-1654</measure>
    <time_frame>At designated time points (up to 1 year post-dose)</time_frame>
    <description>Cmax is the highest observed serum drug concentration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to maximum serum concentration (Tmax) of MK-1654</measure>
    <time_frame>At designated time points (up to 1 year post-dose)</time_frame>
    <description>Tmax is the amount of time required to reach Cmax.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent terminal half-life (t1/2) of MK-1654</measure>
    <time_frame>At designated time points (up to 1 year post-dose)</time_frame>
    <description>t1/2 is the time required for 50% of drug to be cleared from serum.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum concentration of MK-1654 on Day 7 (C7days)</measure>
    <time_frame>Day 7</time_frame>
    <description>Serum concentration of MK-1654 will be measured on Day 7.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum concentration of MK-1654 on Day 14 (C14days)</measure>
    <time_frame>Day 14</time_frame>
    <description>Serum concentration of MK-1654 will be measured on Day 14.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum concentration of MK-1654 on Day 90 (C90days)</measure>
    <time_frame>Day 90</time_frame>
    <description>Serum concentration of MK-1654 will be measured on Day 90.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum concentration of MK-1654 on Day 150 (C150days)</measure>
    <time_frame>Day 150</time_frame>
    <description>Serum concentration of MK-1654 will be measured on Day 150.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum concentration of MK-1654 on Day 365 (C365days)</measure>
    <time_frame>Day 365</time_frame>
    <description>Serum concentration of MK-1654 will be measured on Day 365.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Titer of ADAs to MK-1654 on Day 14: Panels A, B, C, D1 and E1</measure>
    <time_frame>Day 14</time_frame>
    <description>Titers of ADAs to MK-1654 will be measured on Day 14.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Titer of ADAs to MK-1654 on Day 90: Panels A, B, C, D1 and E1</measure>
    <time_frame>Day 90</time_frame>
    <description>Titers of ADAs to MK-1654 will be measured on Day 90.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Titer of ADAs to MK-1654 on Day 150: Panels A, B, C, D1, D2, E1, and E2</measure>
    <time_frame>Day 150</time_frame>
    <description>Titers of ADAs to MK-1654 will be measured on Day 150.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Titer of ADAs to MK-1654 on Day 365: Panels A, B, C, D1, D2, E1, and E2</measure>
    <time_frame>Day 365</time_frame>
    <description>Titers of ADAs to MK-1654 will be measured on Day 365.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Titer of ADAs to MK-1654 on Day 545: Panels D2 and E2</measure>
    <time_frame>Day 545</time_frame>
    <description>Titers of ADAs to MK-1654 will be measured on Day 545.</description>
  </secondary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Anticipated">180</enrollment>
  <condition>Respiratory Tract Infection</condition>
  <condition>Respiratory Syncytial Virus</condition>
  <arm_group>
    <arm_group_label>Panel A: Pre-term MK-1654 Dose 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pre-term infants will receive MK-1654 Dose 1 via intramuscular (IM) injection and will be followed for up to 365 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Panel B: Pre-term MK-1654 Dose 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pre-term infants will receive MK-1654 Dose 2 via IM injection and will be followed for up to 365 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Panel C: Pre-term MK-1654 Dose 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pre-term infants will receive MK-1654 Dose 3 via IM injection and will be followed for up to 365 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Panel D1: Pre-term MK-1654 Dose 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pre-term infants enrolled prior to AM4 will receive MK-1654 Dose 4 via IM injection and will be followed for up to 365 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Panel D2: Pre-term MK-1654 Dose 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pre-term infants enrolled after AM4 will receive MK-1654 Dose 4 via IM injection and will be followed for up to 545 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Panel E1: Full-term MK-1654 Dose 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Full-term infants enrolled prior to AM4 will receive MK-1654 Dose 4 via IM injection and will be followed for up to 365 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Panel E2: Full-term MK-1654 Dose 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Full-term infants enrolled after AM4 will receive MK-1654 Dose 4 via IM injection and will be followed for up to 545 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Pre-term infants will receive placebo via IM injection.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MK-1654</intervention_name>
    <description>Single ascending doses of MK-1654 will be administered via IM injection.</description>
    <arm_group_label>Panel A: Pre-term MK-1654 Dose 1</arm_group_label>
    <arm_group_label>Panel B: Pre-term MK-1654 Dose 2</arm_group_label>
    <arm_group_label>Panel C: Pre-term MK-1654 Dose 3</arm_group_label>
    <arm_group_label>Panel D1: Pre-term MK-1654 Dose 4</arm_group_label>
    <arm_group_label>Panel D2: Pre-term MK-1654 Dose 4</arm_group_label>
    <arm_group_label>Panel E1: Full-term MK-1654 Dose 4</arm_group_label>
    <arm_group_label>Panel E2: Full-term MK-1654 Dose 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo (0.9% sodium chloride [NaCl]) will be administered via IM injection.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  is healthy, based on screening safety laboratory, medical history, and physical&#xD;
             examination results&#xD;
&#xD;
          -  is a pre-term infant (born at 29 weeks to 35 weeks gestational age [inclusive]) or a&#xD;
             full-term infant (born at over 35 weeks gestational age), as confirmed in medical&#xD;
             records&#xD;
&#xD;
          -  weighs ≥2 kg at screening&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  has been recommended to receive palivizumab per local standard of care&#xD;
&#xD;
          -  has ≥1 documented out-of-range safety laboratory results (adjusted for age) at the&#xD;
             time of screening&#xD;
&#xD;
          -  has a known hypersensitivity to any component of the respiratory syncytial virus (RSV)&#xD;
             monoclonal antibody&#xD;
&#xD;
          -  has a history of congenital or acquired immunodeficiency (e.g., splenomegaly)&#xD;
&#xD;
          -  has documented human immunodeficiency virus (HIV) infection, hepatitis B (HBsAg&#xD;
             positive), or hepatitis C (HCV ribonucleic acid [RNA] positive)&#xD;
&#xD;
          -  has known history of functional or anatomic asplenia&#xD;
&#xD;
          -  has a diagnosis of failure to thrive within 14 days of screening&#xD;
&#xD;
          -  has known or history of a coagulation disorder contraindicating intramuscular&#xD;
             injection&#xD;
&#xD;
          -  has received or is expected to receive blood products (except irradiated platelets)&#xD;
             within 3 months prior to enrollment&#xD;
&#xD;
          -  has prior known documented RSV infection&#xD;
&#xD;
          -  has hemodynamically significant congenital heart disease&#xD;
&#xD;
          -  has chronic lung disease of prematurity requiring ongoing medical therapy&#xD;
&#xD;
          -  has a history or current evidence of any condition, therapy, lab abnormality or other&#xD;
             circumstance that, in the opinion of the investigator, might expose the participant to&#xD;
             undue risk by participating in the study, confound the results of the study, or&#xD;
             interfere with the participant's participation for the full duration of the study&#xD;
&#xD;
          -  has any history of malignancy prior to randomization&#xD;
&#xD;
          -  if any of the following apply, the Day 1 visit may be rescheduled for a time when&#xD;
             these criteria are not met:&#xD;
&#xD;
          -  has had a recent febrile illness (rectal temperature 38.1°C [100.5°F] or higher or&#xD;
             axillary temperature 37.8°C [100.0°F] or higher) within 72 hours pre-dose&#xD;
&#xD;
          -  is not up-to-date on required vaccinations per local pediatric vaccine schedule at&#xD;
             time of screening&#xD;
&#xD;
          -  has received inactivated or component vaccines (eg, influenza, hepatitis B) less than&#xD;
             14 days pre-dose&#xD;
&#xD;
          -  has received live, attenuated, non-study licensed pediatric vaccines (e.g., Bacillus&#xD;
             Calmette-Guerin vaccine) less than 30 days pre-dose&#xD;
&#xD;
          -  has received any prior vaccine or monoclonal antibody (mAb) for the prevention of RSV&#xD;
&#xD;
          -  is currently participating in or has participated in an interventional clinical study&#xD;
             with an investigational compound or device at any time prior to first dose&#xD;
             administration or while participating in this current study (participants enrolled in&#xD;
             observational studies may be included and will be reviewed on a case-by-case basis for&#xD;
             approval by the Sponsor)&#xD;
&#xD;
          -  has enrolled previously in this study and been discontinued&#xD;
&#xD;
          -  participant's mother participated in a RSV vaccine clinical study while pregnant and&#xD;
             participant is ≤3 months of chronological age&#xD;
&#xD;
          -  is unable to provide blood sample at screening&#xD;
&#xD;
          -  cannot be adequately followed for safety according to the protocol plan&#xD;
&#xD;
          -  has a parent/legally acceptable representative who is unlikely to adhere to study&#xD;
             procedures, keep appointments, or is planning to relocate during the study&#xD;
&#xD;
          -  is, or has, an immediate family member (eg, spouse, parent/guardian, sibling, or&#xD;
             child) who is directly involved with the study at the site or with the Sponsor&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>8 Months</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Children's Hospital - Colorado ( Site 0067)</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Next Phase Research Alliance, LLC ( Site 0075)</name>
      <address>
        <city>Homestead</city>
        <state>Florida</state>
        <zip>33030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Acevedo Clinical Research Associates ( Site 0025)</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33142</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kapiolani Medical Center for Women and Children ( Site 0027)</name>
      <address>
        <city>Honolulu</city>
        <state>Hawaii</state>
        <zip>96826</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cotton-O'Neil Clinical Research Center PediatricCare ( Site 0081)</name>
      <address>
        <city>Topeka</city>
        <state>Kansas</state>
        <zip>66604</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Mercy Hospital ( Site 0037)</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dartmouth-Hitchcock Medical Center ( Site 0032)</name>
      <address>
        <city>Lebanon</city>
        <state>New Hampshire</state>
        <zip>03766</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SUNY Upstate Medical University Hospital ( Site 0029)</name>
      <address>
        <city>Syracuse</city>
        <state>New York</state>
        <zip>13210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>WakeMed Health and Hospitals ( Site 0033)</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27610</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cincinnati Children's Hospital Medical Center ( Site 0031)</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ohio Pediatric Research Association ( Site 0066)</name>
      <address>
        <city>Dayton</city>
        <state>Ohio</state>
        <zip>45414</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Coastal Pediatric Research ( Site 0028)</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29414</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tribe Clinical Research, LLC ( Site 0082)</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29607</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas Medical Branch at Galveston ( Site 0039)</name>
      <address>
        <city>Galveston</city>
        <state>Texas</state>
        <zip>77555</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tekton Research, Inc. ( Site 0026)</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78240</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Multicare Institute For Research And Innovation ( Site 0035)</name>
      <address>
        <city>Tacoma</city>
        <state>Washington</state>
        <zip>98405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Wisconsin American Family Children's Hospital ( Site 0068)</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53792</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro de Investigacion Clinica Bradford Hill ( Site 0103)</name>
      <address>
        <city>Santiago</city>
        <state>Region M. De Santiago</state>
        <zip>7650698</zip>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital La Florida ( Site 0050)</name>
      <address>
        <city>Santiago</city>
        <state>Region M. De Santiago</state>
        <zip>8242238</zip>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facultad Medicina Universidad de Chile ( Site 0104)</name>
      <address>
        <city>Santiago</city>
        <state>Region M. De Santiago</state>
        <zip>8380453</zip>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Padre Hurtado ( Site 0102)</name>
      <address>
        <city>Santiago</city>
        <state>Region M. De Santiago</state>
        <zip>8880465</zip>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fundacion Hospital San Vicente de Paul ( Site 0097)</name>
      <address>
        <city>Medellin</city>
        <state>Antioquia</state>
        <zip>050010</zip>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universidad Pontificia Bolivariana - Clinica Universitaria Bolivariana ( Site 0098)</name>
      <address>
        <city>Medellin</city>
        <state>Antioquia</state>
        <zip>050036</zip>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro de Atención e Investigación Médica SAS - CAIMED CHIA ( Site 0100)</name>
      <address>
        <city>Chia</city>
        <state>Cundinamarca</state>
        <zip>250001</zip>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MedPlus Medicina Prepagada S.A. ( Site 0095)</name>
      <address>
        <city>Bogota</city>
        <state>Distrito Capital De Bogota</state>
        <zip>110221</zip>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fundacion Universitaria de Ciencias de la Salud - Sociedad de Cirugia ( Site 0099)</name>
      <address>
        <city>Bogota</city>
        <state>Distrito Capital De Bogota</state>
        <zip>111411</zip>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fundacion Valle del Lili ( Site 0090)</name>
      <address>
        <city>Cali</city>
        <state>Valle Del Cauca</state>
        <zip>760032</zip>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital ( Site 0071)</name>
      <address>
        <city>Seoul</city>
        <zip>03080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Severance Hospital Yonsei University Health System ( Site 0073)</name>
      <address>
        <city>Seoul</city>
        <zip>03722</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Samsung Medical Center ( Site 0072)</name>
      <address>
        <city>Seoul</city>
        <zip>06351</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chris Hani Baragwanath Academic Hospital ( Site 0262)</name>
      <address>
        <city>Johannesburg</city>
        <state>Gauteng</state>
        <zip>2013</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tygerberg Hospital ( Site 0261)</name>
      <address>
        <city>Cape Town</city>
        <state>Western Cape</state>
        <zip>7505</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico Universitario de Santiago ( Site 0241)</name>
      <address>
        <city>Santiago de Compostela</city>
        <state>La Coruna</state>
        <zip>15706</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario La Paz ( Site 0242)</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Chile</country>
    <country>Colombia</country>
    <country>Korea, Republic of</country>
    <country>South Africa</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>May 11, 2018</study_first_submitted>
  <study_first_submitted_qc>May 11, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">May 14, 2018</study_first_posted>
  <last_update_submitted>October 18, 2021</last_update_submitted>
  <last_update_submitted_qc>October 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Respiratory Tract Infections</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf</ipd_description>
    <ipd_url>http://engagezone.msd.com/ds_documentation.php</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

